ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO751

Preliminary In Vitro Biocompatibility Test on a New Wearable/Portable Device for Extracorporeal Blood Ultrafiltration

Session Information

  • Bioengineering
    October 25, 2018 | Location: Exhibit Hall, San Diego Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Bioengineering

  • 300 Bioengineering


  • Neri, Mauro, Department of Management and Engineering, Vicenza, VI, Italy
  • Pomare' Montin, Diego, IRRIV, Vicenza, Italy
  • Boscariol, Paolo, Università degli Studi di Padova, Vicenza, Italy
  • Boschetti, Giovanni, University of Padova, Vicenza, Italy
  • de Cal, Massimo, San Bortolo Hospital, Vicenza, Italy
  • Lorenzin, Anna, IRRIV, Vicenza, Italy
  • Palomba, Ilaria, Free University of Bolzano-Bozen, Bolzano, Italy
  • Richiedei, Dario, Università degli Studi di Padova, Vicenza, Italy
  • Trevisani, Alberto, Università degli Studi di Padova, Vicenza, Italy
  • Ronco, Claudio, Ospedale "S. Bortolo" AZ. ULSS 6, Vicenza, Italy

Development of a portable/wearable device for extracorporeal blood ultrafiltration (UF) would lead to impressive clinical,social and economic benefits for patients suffering of chronic kidney disease.
This work presents a new prototype of a wearable device for blood UF, named RAP, able to remove excess fluids from fluid overload patients with chronic kidney disease, and a preliminary in vitro test of potential induced cytotoxicity by measuring apoptosis and necrosis in monocytes
cell line due to indirect contact with the device.


The RAP has been developed as a backpack/trolley configuration. This original layout guarantees the best compromise between miniaturization and ergonomics, introducing an original positioning of many components in 3 independent panels:(a) disposable components,(b) non-disposable devices and (c) electronics. The device has been equipped with a power-bank able to last almost 6 hours and a device for remote monitoring.
Cytotoxicity test was performed by circulating, through the RAP, complete RPMI medium. Monocytes were incubated for 24h in samples taken after 0', 30', 60'. 180' and 360'.


RAP and its design are shown in Figure 1,where also the non-disposable panel and the disposable one, manufactured with addictive technology, are shown. As shown in Figure 2, no inductions of increased necrosis or apoptosis on monocytes with respect to control appeared during a 6h-treatment.


RAP is a new, innovative wearable device for blood ultrafiltration. Arrangement of components can simplify the preparation of the device. Cytotoxic tests demonstrate no induction of cells necrosis or apoptosis. RAP is now ready for human trial.


  • Private Foundation Support